Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxaliplatin, Docetaxel, and Cetuximab in Recurrent/Metastatic SCCHN
NCT00591149Phase 2Terminated
- Sponsor
- University of Kansas Medical Center
- Start
- Jun 2007
- Primary completion
- Apr 2012
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of oxaliplatin in squamous cell carcinoma of the head and neck (HNSCC), sponsored by University of Kansas Medical Center. Primary endpoint: Response Rate at 1 year. Started Jun 2007; status: terminated.
02
Drugs
oxaliplatin
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT00591149.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00591149.